FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®

FORT LEE, N.J., Nov. 19, 2024 /PRNewswire/ -- Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in Bolognana, Italy, to produce RYPLAZIM®. This plasma-derived human plasminogen is indicated for...